Skin Tag Patches

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for use on all skin types, including application on the feet and body. It serves as a suitable alternative to surgical procedures, providing a non-invasive option for patients seeking treatment.

Dosage and Administration

Healthcare professionals should ensure the area of the skin tag is thoroughly cleaned and dried prior to application. The skin tag removal patch should be applied directly to the desired area. It is recommended to leave the patch in place for a duration of a few hours or overnight, depending on the specific needs of the patient.

Once the patch has dried completely, it should be replaced with a new skin tag removal patch to continue the treatment process. Regular monitoring of the application site is advised to assess for any adverse reactions or the need for further intervention.

Contraindications

There are no contraindications associated with the use of this product. It is not classified as a controlled substance, and there are no known risks of abuse, misuse, or dependence. Additionally, there are no specific instructions indicating that the product should not be taken or used under any circumstances.

Warnings and Precautions

For external use only. It is imperative that this product is kept out of reach of children to prevent accidental ingestion. Users are advised not to swallow the product, as it is intended solely for topical application.

To ensure optimal results, individuals should clean their hands thoroughly before applying the product. In the event of any signs of irritation or rash, use should be discontinued immediately. Additionally, the product should not be applied to broken or injured skin, as this may exacerbate irritation or lead to adverse effects.

This product is contraindicated for use in pregnant women. It is essential that healthcare professionals counsel patients accordingly to avoid potential risks during pregnancy.

Side Effects

Patients should be aware that the product is for external use only and must be kept out of reach of children. It is crucial to avoid swallowing the product. In the event of signs of irritation or rash, patients are advised to discontinue use immediately. The product should not be applied to broken or hurt skin. Additionally, it is contraindicated for use in pregnant women.

These warnings highlight the importance of proper usage and the need for caution to prevent adverse reactions.

Drug Interactions

No drug interactions have been identified for the product, indicating that it does not exhibit significant pharmacokinetic or pharmacodynamic interactions with other medications. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Skin Tag Patches (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children to prevent accidental ingestion. It is important to note that the medication should not be swallowed.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant women should not use this medication as it is contraindicated during pregnancy. The potential risks to fetal outcomes have not been established, and the use of this medication in pregnant patients may pose significant harm to the developing fetus. Healthcare professionals are advised to consider alternative treatments for pregnant patients and to counsel women of childbearing potential regarding the risks associated with this medication.

Lactation

Lactating mothers should be aware that this medication is contraindicated for use during pregnancy. There is no specific information available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, healthcare professionals should exercise caution when considering this medication for lactating mothers, and alternative treatments should be evaluated.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide further management and treatment options.

Documentation of the incident, including the substance involved, the amount taken, and the time of ingestion, is crucial for effective management and follow-up care.

Nonclinical Toxicology

The compound is contraindicated for use in pregnant women due to teratogenic effects observed in nonclinical studies. No non-teratogenic effects have been reported in the available data. Additionally, there is no information provided regarding animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available for SPL code 90375-7.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion or misuse. It is important to emphasize the potential risks associated with improper access to the medication, ensuring that patients understand the necessity of safeguarding it in a secure location.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product in a cool and dry place to maintain its integrity and effectiveness. Proper storage conditions are crucial to ensure the product remains within its specified temperature range and is protected from moisture.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Skin Tag Patches, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)